


Dx&Vx

IR Letter

(Dec. 2024)



Dx&Vx Business Roadmap



Medical Diagnostics

Dx&Vx's genomic diagnostics and in vitro diagnostics contribute to reducing healthcare costs and improving treatment outcomes. Genomic diagnostic technologies enable more precise and personalized treatments, combined with new drug developments, driving innovation in the medical field. Our companion diagnostic services enhance the efficacy of both our own and third-party drug developments, minimizing side effects and facilitating the development of personalized treatment options for patients.

Genomic Diagnostics
In Vitro Diagnostics and CDMO
Genomics CRO
Companion Diagnostic Services (CliDex)



Consumer Healthcare

Using our diagnostic technologies, we provide integrated consumer healthcare solutions based on the microbiome for disease prevention, treatment, and management. Our services include health functional foods for prevention, general pharmaceuticals and prescription drugs for treatment, and products for lifestyle and hygiene management. We target the global market and continue to achieve high sales growth.

Microbiome-based Therapeutic Adjuncts
Nutrition Products
Domestic and International CSO
Functional Skincare/Personal Hygiene Products



Drug Development

Our affiliate, Oxford Vacmedix, is preparing to initiate phase 1b clinical trials both domestically and internationally for its cancer vaccine, OVM-200, and our subsidiary Avixgen is about to start phase 2 trials for a dry eye treatment. Additionally, we have a pipeline of in-house developed drugs including microbiome-based therapies, mRNA cancer vaccines, oncology antibodies, and oral obesity treatments.

Microbiome-based Drug Development
ROP and mRNA Cancer Vaccines
Cancer Antibody Drugs, Synthetic Organic Drugs
Ophthalmic Disease Treatment Drugs



Digital Healthcare

Dx&Vx is on the verge of launching K-hub, a bio-pharmaceutical portal, combined with our genomic analysis platform and telemedicine services. We aim to shift from a treatment-centric to a prevention and management-focused approach in healthcare services, ultimately aiming to develop a Clinical Decision Support System (CDSS) to assist medical professionals in their decision-making.

K-hub
Telemedicine Services
AI-based Drug Development Platform
Smart Diagnostic Devices

Performance Summary for December 2024

-  Progressing smoothly in the development of an innovative universal NGS platform
-  Significantly expanding the overseas exports of our healthcare brand products
-  Developing technology to overcome the limitations of mRNA vaccines
-  Exploring market opportunities in Europe at 'MEDICA 2024'
-  Recruiting microbiome expert Director Park Do-young
-  Recruiting Yoon Myung-jin, an executive expert in business development and global deals

Medical Diagnostics

Progressing smoothly in the development of an innovative universal NGS platform

Our company, in collaboration with Pohang University of Science and Technology (POSTECH), is achieving exceptional results in a universal biomaterial development project. This project aims to develop materials with the potential to revolutionize the diagnostics industry. We have successfully completed the initial development phase and have started filing for patents. The technology is expected to replace core materials in diagnostic equipment and be universally applicable across various diagnostic services. We are actively discussing global commercialization and received positive feedback at the recent MEDICA 2024 expo in Germany. Our company now possesses not only a unique innovative vaccine platform but also the world's first diagnostic platform that can standardly supply diagnostic equipment globally. These two innovative platforms are anticipated to generate significant revenue. In collaboration with POSTECH, we continue to work in various fields, including mRNA vaccine development, enhancing our technological prowess and competitive market position.

Consumer Healthcare

Significantly expanding the overseas exports of our healthcare brand products

Our company is currently expanding the export of our healthcare brand products in key international markets including China, Vietnam, Japan, and the USA. Specifically, this year in the Chinese and Vietnamese markets, we have secured export contracts worth approximately 10 billion KRW and 5.6 billion KRW respectively, with full-scale sales set to begin in December. In Japan and the USA, we are preparing to launch sales in collaboration with local companies. Notably, in the Vietnamese market, our 'Ofmom' brand products, designed for mothers and babies, are expected to replicate the success similar to Mummy Ai in China. Additionally, starting from December this year, we plan to collaborate with top-tier Wanghong influencers with over 20 million followers in China to conduct live-stream sales and various promotional events. If the current trend in exploring overseas markets continues, we anticipate that our exports will reach \$14 million next year, representing 22% of our total sales revenue.

Drug Development

Developing technology to overcome the limitations of mRNA vaccines

Our company is collaborating with Pohang University of Science and Technology (POSTECH) to develop a new mRNA vaccine technology under the ARPA-H program, capable of ultra-long-term storage at room temperature. This technology addresses a major drawback of existing mRNA vaccines—complex storage and distribution requirements, offering significant improvements over the need for refrigeration or freezing. We have already confirmed through preliminary research with POSTECH that this new mRNA vaccine could be storable at room temperature for over ten years. This technology is unique worldwide and is expected to improve vaccine distribution and disposal issues, particularly in underdeveloped countries lacking refrigeration facilities. By overcoming challenges such as ultra-low temperature freezing, storage, distribution, and short shelf lives, our technology will enhance global vaccine accessibility, contribute to the improvement of human welfare, and establish a foundation for quick response in pandemic situations, thereby strengthening national health security and commercializing long-term preservation technology for mRNA vaccines.



Drug Development

Exploring market opportunities in Europe at 'MEDICA 2024'

Our company recently attended 'MEDICA 2024', the world's largest medical trade fair, held in Germany, to pursue market expansion into Europe. This event saw participation from around 5,300 companies from over 70 countries, with 83,000 visitors attending. Supported by the government, we set up a booth in the K-Sensor pavilion and actively promoted our innovative pharmaceuticals, mRNA vaccine platform, and digital healthcare services. We engaged in approximately 200 meetings with global biotech and healthcare companies, discussing global sub-licenses for products such as our oral obesity treatment, OVM-200 cancer vaccine, and our ultra-long-term storage mRNA vaccine platform. These meetings were a chance to showcase our technological capabilities and expertise on the global stage. Beyond this exhibition, our company is committed to actively participating in future global expos and conferences to explore business opportunities and achieve tangible results.

Recruiting microbiome expert Director Park Do-young

We are pleased to announce the recent recruitment of microbiome expert Director Park Do-young. Director Park, who majored in microbiomics at Seoul National University, has previously led related research and commercialization efforts at companies like Korean Yakult. At our microbiome research institute, he will spearhead the development and commercialization of the body fat-reducing probiotic Dx2034. This strain is expected to play a leading role in the anti-obesity probiotics market, particularly with our 'Ofmom Diet Probiotic' product. Director Park's expertise will not only enhance our microbiome R&D capabilities but also significantly contribute to various microbiome projects of our parent company, Coree-group. We are committed to securing microbiome intellectual property and building a beneficial bacteria library for the long-term growth in the microbiome field, focusing on the development and commercialization of functional strains.

Recruiting Yoon Myung-jin, an executive expert in business development and global deals

Our company is excited to announce the recent recruitment of Yoon Myung-jin, an executive expert in business development and global deals, as we plan to accelerate our global R&D business expansion and the development of digital therapeutics. A graduate of Korea University, Yoon Myung-jin has accumulated over 30 years of extensive experience at Hyundai Investment Trust Securities, LG Life Sciences, Samil PwC, and Shaperon, specializing in business development, overseas operations, global investment, and strategic planning. At our company, he will lead the commercialization of medical diagnostics, bio healthcare, new drug development, license-outs, and AI-based digital healthcare services, contributing to an increase in profitability. Additionally, he will focus on discovering foreign investment opportunities to generate financial synergies with our parent company, Coree-group.

Compliance Notice

This document is prepared solely for informational purposes to assist investors' understanding. It is based on data and information considered reliable, and has been diligently compiled; however, we do not guarantee its accuracy or completeness. Investment decisions should be made based on the investor's own judgment and responsibility. Under no circumstances can this material be used as legal evidence of liability for investment results.